Jasper Therapeutics jumps after positive briquilimab trial
Shares up 15% premarket (Il Sole 24 Ore Radiocor) - New York, 14 Oct - Shares in Jasper Therapeutics jumped in premarket trading after the clinical-stage biotechnology company reported positive data from a trial of its novel antibody therapy briquilimab.
The company said 14 of 15 participants enrolled in the trial achieved a clinical response, 10 of 12 participants in the 120mg cohort achieved a complete response, while there were no serious adverse events.
'We are very excited to report positive data from the SPOTLIGHT study, our first readout from a clinical trial evaluating briquilimab in chronic urticaria,' said Ronald Martell, President and Chief Executive Officer of Jasper.
At 1216 GMT Jasper Therapeutics shares were up 15%.
AAA-Sje
(RADIOCOR) 14-10-24 14:31:35 (0389) 5 NNNN